Zobrazeno 1 - 10
of 11
pro vyhledávání: '"K F, Thomson"'
Autor:
K. F. Thomson, W.J. Cunliffe
Publikováno v:
Clinical and Experimental Dermatology. 25:299-301
Acne fulminans is characterized by the sudden onset of a severe, ulcerative acne associated with systemic features. Response to traditional acne therapies is poor. We have recognized a subset of patients with acne of a severity comparable to that of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a5b68e757aaf66bbe271fea9d30083d
https://doi.org/10.1046/j.1365-2230.2000.00647.x
https://doi.org/10.1046/j.1365-2230.2000.00647.x
Autor:
M J D Goodfield, K F Thomson
Publikováno v:
The Journal of dermatological treatment. 12(3)
BACKGROUND: The use of thalidomide in inflammatory cutaneous disorders has increased over recent years. Its use in cutaneous lupus erythematosus is now well documented, although most groups favour high-dose regimes (200 mg twice daily), where side ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3433bce900b76417f60df61c8925c6a
https://pubmed.ncbi.nlm.nih.gov/12243705
https://pubmed.ncbi.nlm.nih.gov/12243705
Autor:
K F, Thomson, W J, Cunliffe
Publikováno v:
Clinical and experimental dermatology. 25(4)
Acne fulminans is characterized by the sudden onset of a severe, ulcerative acne associated with systemic features. Response to traditional acne therapies is poor. We have recognized a subset of patients with acne of a severity comparable to that of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ddb36b150b6b47a73597d69191127ad
https://pubmed.ncbi.nlm.nih.gov/10971490
https://pubmed.ncbi.nlm.nih.gov/10971490
Autor:
S M, Wilkinson, K F, Thomson
Publikováno v:
Contact dermatitis. 42(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::64625203618a3af003729e0b34337ed9
https://pubmed.ncbi.nlm.nih.gov/10727167
https://pubmed.ncbi.nlm.nih.gov/10727167
Publikováno v:
Contact dermatitis. 42(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3c1e342726a7d00b8a57040d64801fb5
https://pubmed.ncbi.nlm.nih.gov/10703643
https://pubmed.ncbi.nlm.nih.gov/10703643
Autor:
K F, Thomson, S M, Wilkinson
Publikováno v:
The British journal of dermatology. 142(1)
Cosmetic contact allergy is commonly seen in patients undergoing patch testing, with fragrance one of the most frequently implicated ingredients. Many cosmetics contain plant extracts either as a fragrance or for medicinal properties. With a vogue fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::64716e2e3a3ae38f3b2aba40fc49ae45
https://pubmed.ncbi.nlm.nih.gov/10651699
https://pubmed.ncbi.nlm.nih.gov/10651699
Publikováno v:
The British journal of dermatology. 141(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3ffb7ae7b83f04674992e4b72d8b4649
https://pubmed.ncbi.nlm.nih.gov/10583094
https://pubmed.ncbi.nlm.nih.gov/10583094
Publikováno v:
Contact dermatitis. 37(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c84faf8456794e009a4cac79039eea
https://pubmed.ncbi.nlm.nih.gov/9385521
https://pubmed.ncbi.nlm.nih.gov/9385521
Autor:
A. S. Highet, K. F. Thomson
Publikováno v:
Clinical and Experimental Dermatology. 25:659-660
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb354e47dffe82bb1014c49c8ca36c77
https://doi.org/10.1046/j.1365-2230.2000.00730-5.x
https://doi.org/10.1046/j.1365-2230.2000.00730-5.x
Publikováno v:
Journal of Clinical Pathology. 54:413-413
Antinuclear antibody (ANA) negative lupus has long been recognised as a distinct entity affecting a small number of patients with systemic lupus erythematosus (SLE).1 Initial estimates of the prevalence of this entity (5% of patients with lupus) were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a02d801b75eb445094fb7ad4e35930f
https://doi.org/10.1136/jcp.54.5.413
https://doi.org/10.1136/jcp.54.5.413